HEALTH OF WOMAN. 2019.8(144): 7–11; doi 10.15574/HW.2019.144.7

L.G. Nazarenko^1,2, O.V. Demina^2
1Kharkiv medical Academy of postgraduate education
²CNE «Clinical Maternity Hospital № 6» of Kharkiv City Council

In modern obstetrics, there is an increase in the frequency of pathological conditions, combined with the sign of abnormal syvasive of the placenta, the spectrum of which includes placenta accreta, placenta increta, placenta percreta. The most favored definition is placenta accreta, in international sources of information – placenta accreta spectrum. This pathology is the leading cause of life-threatening hemorrhage, which often requires blood transfusion, hysterectomy. The issues of prediction and diagnosis are relevant.

Contemporary ideas about the etiology and pathogenesis of placental growth are covered, risk factors as a basis for clinical prognosis are substantiated and specified. The basic elements of diagnostics of placental growth in the observation of the pregnant woman are presented. The necessity of prenatal hospitalization and delivery in conditions of providing modern technologies of blood circulation, surgical help, highly professional multidisciplinary team is emphasized.

Key words: placenta, growth, caesarean section, prognosis, diagnosis.

REFERENCES

1. Vinnitskiy AA, Shmakov RG, Byichenko VG. 2017. Sovremennyie metody instrumentalnoi diagnostiki vrastaniya platsenty. Akusherstvo i ginekologiya 3:12–17.

2. Vinnitskiy AA, Shmakov RG. 2017. Sovremennyie predstavleniya ob etiopatogeneze vrastaniya platsenty i perspektivy ego prognozirovaniya molekulyarnymi metodami diagnostiki. Akusherstvo i ginekologiya 2: 5–10.

3. Saveleva GM, Kurtser MA, Breslav IYu i dr. 2015. Vrastanie predlezhaschey platsentyi (alacenta accreta) u patsientok s rubtsom na matke posle kesareva secheniya. Kliniko-morfologicheskoe sopostavlenie. Akusherstvo i ginekologiya 1: 41–45.

4. Tshay VB, Yametov PK, Vergunov NA. 2017. Beremennost v rubtse na matke posle kesareva secheniya. Sovremennoe sostoyanie problemyi. Diagnostika. Klinika. Vrachebnaya taktika. Akusherstvo i ginekologiya 3:5–10.

5. Baldwin HJ, Patterson JA, Nippita TA et al. 2018. Antecedents of abnormally invasive placenta in primiparous women: risk associated with gynecologic procedures. Obstet Gynecol. 131: 227–233. https://doi.org/10.1097/AOG.0000000000002434; PMid:29324602

6. Berkley EM, Abuhamad AZ. 2013. Prenatal diagnosis of placenta accreta: is sonography all we need? J. Ultrasound Med. 32:1345–1350. https://doi.org/10.7863/ultra.32.8.1345; PMid:23887942

7. Bowman ZS, Eller AG, Kennedy AM et al. 2014. Interobserver variability of sonography for prediction of placenta accrete. J. Ultrasound. Med. 33: 2153–2158. https://doi.org/10.7863/ultra.33.12.2153; PMid:25425372

8. Bowman ZS, Eller AG, Bardsley TR en al. 2014. Risk factors for placenta accreta: a large prospective cohort. Am. J .Perinatol. 31: 799–804. https://doi.org/10.1055/s-0033-1361833; PMid:24338130

9. Comstock CH, Bronsteen RA. 2014. The antenatal diagnosis of placenta accrete. BJOG:121: 122. https://doi.org/10.1111/1471-0528.12557; PMid:24373591

10. Desai N, Krantz D, Roman A et al. 2014.Elevated first trimester PAPP-a is associated with increased risk of placenta accrete. Prenat. Diagn. 34: 159–162. https://doi.org/10.1002/pd.4277; PMid:24226752

11. El Behery MM, Rasha LE, El Alfy Y. 2010. Cell-free placental mRNA in maternal plasma to predict placental invasion in patients with placenta accrete. Int. J. Gynaecol. Obstet. 109: 30–33. https://doi.org/10.1016/j.ijgo.2009.11.013; PMid:20070963

12. Eshkoli TE, Weintraub AY, Sergienko R, Sheiner E. 2013. Placenta accreta: risk factors, perinatal outcomes, and consequences for subsequent births. Am. J. Obstet. Gynecol. 208: 219.e1–219.e7. https://doi.org/10.1016/j.ajog.2012.12.037; PMid:23313722

13. Erfani H, Fox KA, Shah SC et al. 2019. Unexpected Placenta Accreta Spectrum (PAS): Improved outcomes with Multidisciplinary Team Care. Am. J. Obstet. Gynecol. 220;1; Supplement:S127. https://doi.org/10.1016/j.ajog.2018.11.190

14. Ersoy AO, Oztas E, Ozler S et al. 2016. Can venous ProBNP levels predict placenta accreta? J. Matern. Fetal. Neonatal. Med. 29: 4020–4024. https://doi.org/10.3109/14767058.2016.1152576; PMid:26864469

15. Garmi G, Salim R. 2012. Epidemiology, etiology, diagnosis, and management of placenta accrete. Obstet. Gynecol. Int.: 873–929. https://doi.org/10.1155/2012/873929; PMid:22645616 PMCid:PMC3356715

16. Irving C, Hertig AT. 1937. A study of placenta accrete. Surg. Gynecol. Obstet. 64: 178–200.

17. Jauniaux E, Collins S, Burton GJ. 2018, January.  Placenta accreta spectrum: pathophysiology and evidence-based anatomy for prenatal ultrasound imaging. American Journal of Obstetrics & Gynecology 218;1:75–87. https://doi.org/10.1016/j.ajog.2017.05.067; PMid:28599899

18. Kawashima A, Koide K, Ventura W et al. 2014. Effects of maternal smoking on the placental expression of genes related to angiogenesis and apoptosis during the first trimester. PLoS One. 9: e106-140. https://doi.org/10.1371/journal.pone.0106140; PMid:25165809 PMCid:PMC4148425

19. Kupferminc MJ, Tamura RK, Wigton TR et al. 1993. Placenta accreta is associated with elevated maternal serum alpha-fetoprotein. Obstet. Gynecol. 82: 266–269.

20. Levels of maternal care. Obstetric Care Consensus № 2. American College of Obstetricians and Gynecologists. Obstet Gynecol. 125: 502–515. 2015. https://doi.org/10.1097/01.AOG.0000460770.99574.9f; PMid:25611640

21. Lyell DJ, Faucett AM, Baer RJ et al. 2015. Maternal serum markers, characteristics and morbidly adherent placenta in women with previa. J. Perinatol. 35: 570–574. https://doi.org/10.1038/jp.2015.40; PMid:25927270

22. Marshall NE, Fu R, Guise JM et al. 2011. Impact of multiple cesarean deliveries on maternal morbidity: a systematic review. Am. J. Obstet. Gynecol. 205:262.e1–262.e8. https://doi.org/10.1016/j.ajog.2011.06.035; PMid:22071057

23. Melcer Y, Jauniaux E, Maymon S et al. 2018, April.  Impact of targeted scanning protocols on perinatal outcomes in pregnancies at risk of placenta accreta spectrum or vasa previa. American Journal of Obstetrics & Gynecology 218; 4:443.e1–443.e8. https://doi.org/10.1016/j.ajog.2018.01.017; PMid:29353034

24. Miller DA, Chollet JA, Goodwin TM. 1997. Clinical risk factors for placenta previa-placenta accrete. Am. J .Obstet. Gynecol. 177:210–214. https://doi.org/10.1016/S0002-9378(97)70463-0

25. Mogos MF, Salemi JL, Ashley M et al. 2016. Recent trends in placenta accreta in the United States and its impact on maternal-fetal morbidity and healthcare-associated costs, 1998–2011. J. Matern. Fetal Neonatal Med. 29: 1077–1082. https://doi.org/10.3109/14767058.2015.1034103; PMid:25897639

26. Cahill Alison G, Richard Beigi, Phillips R Heine, Silver Robert M, Joseph R. 2018, December.  Wax Placenta Accreta Spectrum The Society of Gynecologic Oncology endorses this document. American Journal of Obstetrics & Gynecology 219;6:B2–B16. https://doi.org/10.1016/j.ajog.2018.09.042; PMid:30471891

27. Rac M, McIntire1 D, Johnson-Welch Sarah et al. 2015, January.  Degree of placental invasion and the Placenta Accreta Index. Am. J .Obstet. Gynecol. 212;1;Supplement: S187–S188. https://doi.org/10.1016/j.ajog.2014.10.403

28. Read JA, Cotton DB, Miller FC. 1980. Placenta accreta: changing clinical aspects and outcome. Obstet. Gynecol. 56:31–34.

29. Shellhaa CS, Gilbert S, Landon MB et al. 2009. The frequency and complication rates of hysterectomy accompanying cesarean delivery. Eunice Kennedy Shriver National Institutes of Health and Human Development Maternal-Fetal Medicine Units Network. Obstet. Gynecol.  114: 224–229

30. Silver RM, Landon MB, Rouse DJ. 2006. Maternal morbidity associated with multiple repeat cesarean deliveries. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Obstet. Gynecol. 107:1226–1232. https://doi.org/10.1097/01.AOG.0000219750.79480.84; PMid:16738145

31. Tantbirojn P, Crum CD, Parast MM. 2008. Pathophysiology of placenta creta: the role of deciduas and extravillous cytotrophoblast. Placenta 29 (7):639–645. https://doi.org/10.1016/j.placenta.2008.04.008; PMid:18514815

32. Usta IM, Hobeika EM, Musa AA et al. 2005. Placenta previa-accreta: risk factors and complications. / Am. J. Obstet. Gynecol. 193: 1045–1049. https://doi.org/10.1016/j.ajog.2005.06.037; PMid:16157109

33. Wu S, Kocherginsky M, Hibbard JU et al. 2005. Abnormal placentation: twenty-year analysis. Am. J. Obstet. Gynecol. 192: 1458–1461. https://doi.org/10.1016/j.ajog.2004.12.074; PMid:15902137

34. Zelop C, Nadel A, Frigoletto FD et al. 1992. Placenta accreta/percreta/increta: a cause of elevated maternal serum alpha-fetoprotein. Obstet. Gynecol. 80: 693–694.

35.1. Zhou J, Li J, Yan P et al. 2014. Maternal plasma levels of cell-free beta-HCG mRNA as a prenatal diagnostic indicator of placenta accrete. Placenta 35: 691–695. https://doi.org/10.1016/j.placenta.2014.07.007; PMid:25063251